Initiation of cell therapy research and development program for adult T-Cell leukemia / lymphoma (ATLL)

启动成人T细胞白血病/淋巴瘤（ATLL）的细胞疗法研究和开发计划

TOKYO, July 11, 2024 /PRNewswire/ -- The National Cancer Center (Tokyo, Japan) and The University of Pennsylvania (Philadelphia, PA, USA) have licensed patent rights directed to a chimeric antigen receptor T cell therapy that targets the chemokine receptor CCR4 (CCR4 CAR-T cell therapy) to ARC Therapies Inc.

东京，2024年7月11日/PRNewswire/--国家癌症中心（日本东京）和宾夕法尼亚大学（美国宾夕法尼亚州费城）拥有针对针对趋化因子受体CCR4（CCR4 CAR-T细胞疗法）的嵌合抗原受体T细胞疗法的专利权，以ARC Therapes Inc。

(CEO: Rami Suzuki, Headquarters: Shinjuku-ku, Tokyo), a startup originating from the National Cancer Center. This agreement marks the commencement of ARC Therapies, Inc.'s research and development of a cell therapy targeting T-cell cancers, including adult T-cell leukemia/lymphoma (ATLL), which is prevalent in Japan.

（CEO：Rami Suzuki，总部：东京新宿区），这是一家起源于国家癌症中心的初创公司。该协议标志着ARC Therapes，Inc.开始研究和开发针对T细胞癌的细胞疗法，包括在日本流行的成人T细胞白血病/淋巴瘤（ATLL）。

Furthermore, the potential application of CCR4 CAR-T cell therapy to solid cancers will also be pursued..

此外，还将寻求CCR4 CAR-T细胞疗法在实体癌中的潜在应用。。

The National Cancer Center, established in 1962, is a leading cancer institute in Japan. The University of Pennsylvania pioneered the foundational research and co-development activities that led to the first CAR-T cell approved by the FDA in 2017 and continues to be a leader in CAR-T cell research, including next-generation therapies.

1962年成立的国家癌症中心是日本领先的癌症研究所。宾夕法尼亚大学开创了基础研究和共同开发活动，导致2017年FDA批准了第一个CAR-T细胞，并继续成为CAR-T细胞研究（包括下一代疗法）的领导者。

ARC Therapies Inc., established in May 2022, is a National Cancer Center Japan-certified startup that promotes the research and clinical development of new cell therapies using cutting-edge research..

ARC Therapes Inc.成立于2022年5月，是一家经日本国家癌症中心认证的初创公司，利用尖端研究促进新细胞疗法的研究和临床开发。。

Hiroyuki Mano, Director of the National Cancer Center Research Institute, commented:

国家癌症中心研究所所长Hiroyuki Mano评论道：

'At the National Cancer Center, we are consistently promoting a comprehensive approach from understanding the mechanisms of carcinogenesis to the development of treatment and diagnostic methods for various cancers. We are pleased that one of the outcomes of our international collaborative research, the CCR4 CAR-T cell therapy, has led to a licensing arrangement for the development of potential new treatments by a startup originating from the National Cancer Center.

“在国家癌症中心，我们一直在推动从了解致癌机制到开发各种癌症的治疗和诊断方法的综合方法。。

We expect this arrangement to accelerate the practical application of new T-cell therapies originating from the National Cancer Center.'.

我们期望这种安排能够加速来自国家癌症中心的新T细胞疗法的实际应用。”。

Rami Suzuki, CEO of ARC Therapies Inc., commented:

ARC Therapes Inc.首席执行官Rami Suzuki评论道：

'We are committed to the research and development of the CCR4 CAR-T cell therapy licensed from the National Cancer Center and the University of Pennsylvania. The potential long-lasting efficacy of chimeric antigen receptor T cell therapy is well-known, and we hope that our efforts will provide valuable treatment options for cancer patients.'.

“我们致力于国家癌症中心和宾夕法尼亚大学许可的CCR4 CAR-T细胞疗法的研究和开发。嵌合抗原受体T细胞疗法的潜在持久功效是众所周知的，我们希望我们的努力将为癌症患者提供有价值的治疗选择。”。

Glossary:

词汇表：

*1 CCR4:

*1 CCR4：

CCR4 is a chemokine receptor primarily expressed on lymphocytes that migrate to the skin. It is found on the surface of cells in Adult T-Cell Leukemia/Lymphoma (ATLL), Peripheral T-Cell Lymphoma (PTCL), and Cutaneous T-Cell Lymphoma (CTCL). The anti-CCR4 antibody 'mogamulizumab' is approved as a therapeutic drug for the aforementioned three types of cancer.

CCR4是一种趋化因子受体，主要在迁移到皮肤的淋巴细胞上表达。它存在于成人T细胞白血病/淋巴瘤（ATLL），外周T细胞淋巴瘤（PTCL）和皮肤T细胞淋巴瘤（CTCL）的细胞表面。抗CCR4抗体“mogamulizumab”被批准为上述三种癌症的治疗药物。

Additionally, CCR4 is expressed on regulatory T cells surrounding tumors, indicating potential for solid cancer treatment through regulatory T cell removal therapy..

此外，CCR4在肿瘤周围的调节性T细胞上表达，表明通过调节性T细胞去除疗法治疗实体癌的潜力。。

*2 CCR4 CAR-T cell therapy:

*2 CCR4 CAR-T细胞疗法：

Recombinant T cells will be created by introducing a gene that combines an antibody (single chain) that binds specifically to CCR4 with an intracellular signal transduction domain into leukocytes collected from the patient. When injected into the patient, it is hoped that these cells will migrate and accumulate in tumor tissues expressing CCR4, become activated, and attack the cancer..

重组T细胞将通过引入一种基因来产生，该基因将特异性结合CCR4的抗体（单链）与细胞内信号转导结构域结合到从患者收集的白细胞中。当注射到患者体内时，希望这些细胞会迁移并积聚在表达CCR4的肿瘤组织中，被激活并攻击癌症。。

*3 Adult T-Cell Leukemia/Lymphoma (ATLL):

*3成人T细胞白血病/淋巴瘤（ATLL）：

ATLL is a T-cell lymphomas/ lymphoid malignancies (neoplasms) that develops in patients infected with Human T-Cell Leukemia Virus Type 1 (HTLV-1). HTLV-1 infection is observed in specific regions of Japan, making ATLL a characteristic tumor of Japan. The government is focusing on countermeasures as a national issue.

。在日本的特定地区观察到HTLV-1感染，使ATLL成为日本的特征性肿瘤。政府将对策作为一个全国性的问题来关注。

Although anti-CCR4 antibody treatment has been successful for blood-type ATLL, recurrence remains a problem, and there is currently no effective treatment for lymphoma-type ATLL..

尽管抗CCR4抗体治疗已成功用于血型ATLL，但复发仍然是一个问题，目前尚无针对淋巴瘤型ATLL的有效治疗方法。。

University of Pennsylvania Financial Disclosure:

宾夕法尼亚大学财务披露：

Penn may receive forward-looking financial consideration related to the licensing of certain Penn intellectual property to ARC Therapies, Inc.

宾夕法尼亚大学可能会收到与向ARC Therapes，Inc.许可某些宾夕法尼亚大学知识产权有关的前瞻性财务考虑。

Enquiries

查询

On Research

关于研究

Keisuke Watanabe, MD PhDSenior Staff Scientist at the National Cancer Center Research InstituteE-mail: keiswata@ncc.go.jp

美国国家癌症中心研究所（National Cancer Center Research Institute）医学博士兼研究员渡边敬介（Keisuke Watanabe）邮件：keiswata@ncc.go.jp

Media Inquiries

媒体查询

Office of Public Relations, Strategic Planning Bureau,National Cancer Center (Tsukiji Campus)E-mail： ncc-admin@ncc.go.jp

ncc-admin@ncc.go.jp

ARC Therapies Inc.Rami SuzukiCEO of ARC Therapies Inc.E-mail： rami.suzuki@acrtherapies.inc

ARC Therapes Inc.ARC Therapes Inc.的Rami SuzukiCEO.电子邮件：rami.suzuki@acrtherapies.inc

SOURCE ARC Therapies Inc.

SOURCE ARC Therapes公司。